Immunotoxins in Cancer Therapy

Jansen, F. K.; Blazy, C.; Blythman, Hildur E.; Bourrié, Bernard; Carayon, Pierre; Casellas, Pierre; Derocq, Jean-Marie; Dussossoy, D.; Gros, Pierre; Gros, Olivier; Laurent, Guy; Richer, G.; Vidal, Hubert

doi:10.1007/978-1-4684-5574-8_7

Cited by 1 publication

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(5) Irradiation of the APC with a different therapeutic wavelength in the presence of molecular oxygen causes reactive oxygen species (ROS) production which oxidatively damage the cell and induce cell death. scale protein production at high purity and quality [164,165]. As stated by Chandramohan et al (2013), the therapeutic success of a tumor-targeting agent is dependent on 2 critical factors: (1) efficient delivery to the tumor site at adequate concentration; and (2) uniform distribution throughout the neoplastic lesion [166].…”

Section: Egfr-specific Recombinant Immunotoxins Anti-egfr Immunotoxinmentioning

confidence: 99%

“…Early developers of ITs were able to harness the activity of various plant and bacterial toxins. Toxins such as diphtheria toxin (DT), ricin A or Pseudomonas exotoxin A (also known as ETA or PE) are endowed with their own translocation domains and other components that can facilitate endosomal escape -a major rate-limiting step in the delivery of therapeutic macromolecules to the cytoplasm of cells [164]. With this peculiar characteristic, such toxins display higher toxicity than chemical agents; a single toxin molecule is enough to kill a cell while 10000 to 100000 molecules of toxic chemicals are required to produce the same effect [168][169][170][171].…”

Section: Egfr-specific Recombinant Immunotoxins Anti-egfr Immunotoxinmentioning

confidence: 99%

See 1 more Smart Citation

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies

et al. 2020

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angiogenesis. This multi-dimensional role of EGFR in the progression and aggressiveness of cancer, has evolved from conventional to more targeted therapeutic approaches. With the advent of hybridoma technology and phage display techniques, the first anti-EGFR monoclonal antibodies (mAbs) (Cetuximab and Panitumumab) were developed. Due to major limitations including host immune reactions and poor tumor penetration, these antibodies were modified and used as guiding mechanisms for the specific delivery of readily available chemotherapeutic agents or plants/bacterial toxins, giving rise to antibody-drug conjugates (ADCs) and immunotoxins (ITs), respectively. Continued refinement of ITs led to deimmunization strategies based on depletion of B and T-cell epitopes or substitution of non-human toxins leading to a growing repertoire of human enzymes capable of inducing cell death. Similarly, the modification of classical ADCs has resulted in the first, fully recombinant versions. In this review, we discuss significant advancements in EGFR-targeting immunoconjugates, including ITs and recombinant photoactivable ADCs, which serve as a blueprint for further developments in the evolving domain of cancer immunotherapy.

show abstract

Section: Egfr-specific Recombinant Immunotoxins Anti-egfr Immunotoxinmentioning

confidence: 99%

Section: Egfr-specific Recombinant Immunotoxins Anti-egfr Immunotoxinmentioning

confidence: 99%

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies

et al. 2020

View full text Add to dashboard Cite

show abstract

Immunotoxins in Cancer Therapy

Cited by 1 publication

References 12 publications

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies

Contact Info

Product

Resources

About